Breast Cancer:@0.781548:0.035749:0.914554:0.035749:0.914554:0.019993:0.781548:0.019993:0.011045:0.005717:0.012508:0.013143:0.007466:0.006523:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
49:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
cancer, a particularly aggressive type of :@0.084848:0.096166:0.481073:0.096166:0.481073:0.080410:0.084848:0.080410:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.008505:0.013143:0.008505:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.008505:0.013143:0.012950:0.012950:0.005707:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.008505:0.006523:0.010314:0.013123:0.012508:0.008505:0.012604:0.006042:0.005330
breast cancer.:@0.084848:0.112345:0.220648:0.112345:0.220648:0.096589:0.084848:0.096589:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004374:0.005330
INITIAL WORK-UP AFTER  :@0.084848:0.145364:0.357616:0.145364:0.357616:0.125767:0.084848:0.125767:0.006585:0.017404:0.006585:0.009878:0.006585:0.017404:0.010348:0.006585:0.021167:0.019756:0.013641:0.014581:0.009878:0.015052:0.013170:0.006585:0.017404:0.011289:0.009878:0.012230:0.013641:0.006538:0.006585
A BREAST-CANCER DIAGNOSIS:@0.084848:0.164492:0.430100:0.164492:0.430100:0.144895:0.084848:0.144895:0.017404:0.006585:0.013641:0.013641:0.012230:0.017404:0.012230:0.009878:0.009878:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641:0.006585:0.016463:0.006585:0.017404:0.019756:0.017404:0.019756:0.012230:0.006585:0.012230
Staging tests that should be performed :@0.084848:0.182965:0.481088:0.182965:0.481088:0.167209:0.084848:0.167209:0.009583:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.010910:0.006523:0.012508:0.007466:0.006523:0.007466:0.010910:0.006523:0.011738:0.013143:0.006523:0.010910:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.010910:0.013123:0.012508:0.010910:0.013123:0.012508:0.006710:0.006042:0.012604:0.006317:0.018049:0.012508:0.013181:0.005330
after a breast-cancer diagnosis are a :@0.084848:0.199144:0.481069:0.199144:0.481069:0.183388:0.084848:0.183388:0.013143:0.006042:0.006523:0.012508:0.005792:0.014008:0.013143:0.014008:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.014008:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.014008:0.013143:0.005715:0.012508:0.014008:0.013143:0.005330
chest x-ray, abdominal ultrasound, blood :@0.084848:0.215323:0.481082:0.215323:0.481082:0.199567:0.084848:0.199567:0.012450:0.011738:0.012508:0.007466:0.006523:0.007237:0.009236:0.006388:0.005792:0.013143:0.010314:0.005330:0.007241:0.013143:0.013123:0.013181:0.012604:0.018049:0.003848:0.011738:0.013143:0.003848:0.007245:0.011699:0.003848:0.006523:0.005792:0.013143:0.007466:0.012604:0.011699:0.011738:0.013181:0.005330:0.007231:0.013123:0.003848:0.012604:0.012604:0.013181:0.005330
tests (which must include a liver function :@0.084848:0.231503:0.481107:0.231503:0.481107:0.215747:0.084848:0.215747:0.006523:0.012508:0.007466:0.006523:0.007466:0.008024:0.007100:0.015990:0.011738:0.003848:0.012450:0.011738:0.008014:0.018049:0.011699:0.007466:0.006523:0.008024:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.008024:0.013143:0.008024:0.003848:0.003848:0.010660:0.012508:0.005792:0.008014:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
test and a calcium level). Tumour markers :@0.084848:0.247682:0.481096:0.247682:0.481096:0.231926:0.084848:0.231926:0.006523:0.012508:0.007466:0.006523:0.005969:0.013143:0.011738:0.013181:0.005973:0.013143:0.005975:0.012450:0.013143:0.003848:0.012450:0.003848:0.011699:0.018049:0.005975:0.003848:0.012508:0.010660:0.012508:0.003848:0.007100:0.005330:0.005984:0.007310:0.011699:0.018049:0.012604:0.011699:0.005792:0.005963:0.018049:0.013143:0.005792:0.009660:0.012508:0.005792:0.007466:0.005330
are not standard tests, but may aid in the :@0.084848:0.263861:0.481078:0.263861:0.481078:0.248105:0.084848:0.248105:0.013143:0.005715:0.012508:0.006177:0.011738:0.012604:0.006523:0.006177:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005675:0.013181:0.006177:0.006523:0.012508:0.007466:0.006523:0.007466:0.005330:0.006177:0.013123:0.011699:0.006523:0.006177:0.018049:0.013143:0.010314:0.006177:0.013143:0.003848:0.013181:0.006188:0.003848:0.011738:0.006177:0.006523:0.011738:0.012508:0.005330
overall assessment  and monitoring  of a :@0.084848:0.280040:0.481094:0.280040:0.481094:0.264284:0.084848:0.264284:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.010930:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.018065:0.012508:0.011738:0.006523:0.005330:0.005590:0.013143:0.011738:0.013181:0.010930:0.018049:0.012604:0.011738:0.003848:0.006523:0.012604:0.005792:0.003848:0.011738:0.012950:0.005330:0.005580:0.012604:0.006042:0.010930:0.013143:0.005330
patient following diagnosis.:@0.084848:0.296220:0.337963:0.296220:0.337963:0.280464:0.084848:0.280464:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330
INDICATIONS FOR AN MRI BREAST:@0.084848:0.329267:0.459733:0.329267:0.459733:0.309670:0.084848:0.309670:0.006585:0.017404:0.016463:0.006585:0.018344:0.017404:0.009878:0.006585:0.019756:0.017404:0.012230:0.006585:0.011289:0.019756:0.013641:0.006585:0.017404:0.017404:0.006585:0.021167:0.013641:0.006585:0.006585:0.013641:0.013641:0.012230:0.017404:0.012230:0.009878
An MRI of the breast is not a standard imag-:@0.084848:0.347744:0.475831:0.347744:0.475831:0.331988:0.084848:0.331988:0.014047:0.011545:0.004022:0.017491:0.011488:0.004156:0.004022:0.012411:0.005850:0.004022:0.006331:0.011545:0.012315:0.004022:0.012931:0.005521:0.012315:0.012950:0.007274:0.006331:0.004022:0.003656:0.007274:0.004022:0.011545:0.012411:0.006331:0.004022:0.012950:0.004022:0.007274:0.006331:0.012950:0.011545:0.012989:0.012950:0.005482:0.012989:0.004022:0.003656:0.017857:0.012950:0.012758:0.006388
ing technique in all breast-cancer patients. :@0.084848:0.363923:0.481065:0.363923:0.481065:0.348167:0.084848:0.348167:0.003656:0.011545:0.012758:0.004791:0.006331:0.012315:0.012257:0.011545:0.011545:0.003656:0.012931:0.011507:0.012315:0.004791:0.003656:0.011545:0.004791:0.012950:0.003656:0.003656:0.004791:0.012931:0.005521:0.012315:0.012950:0.007274:0.006331:0.006196:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.004791:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005328:0.005330
Doing an MRI pre-operatively increased :@0.084848:0.380102:0.481065:0.380102:0.481065:0.364346:0.084848:0.364346:0.014124:0.012411:0.003656:0.011545:0.012758:0.012007:0.012950:0.011545:0.012007:0.017491:0.011488:0.004156:0.012007:0.012931:0.005519:0.012315:0.006196:0.012411:0.012931:0.012315:0.005600:0.012950:0.006331:0.003656:0.010468:0.012315:0.003656:0.010122:0.012007:0.003656:0.011545:0.012257:0.005521:0.012315:0.012950:0.007274:0.012315:0.013183:0.005330
mastectomy  rates  and  was  not  shown  to :@0.084848:0.396281:0.481101:0.396281:0.481101:0.380525:0.084848:0.380525:0.017857:0.012950:0.007274:0.006331:0.012315:0.012257:0.006331:0.012411:0.017857:0.010122:0.005330:0.002913:0.005600:0.012950:0.006331:0.012315:0.007274:0.005330:0.002911:0.012950:0.011545:0.012989:0.005330:0.002913:0.015798:0.012950:0.007274:0.005330:0.002911:0.011545:0.012411:0.006331:0.005330:0.002911:0.007274:0.011545:0.012411:0.015798:0.011545:0.005330:0.002911:0.006331:0.012598:0.005330
reduce  re-excision  rates.   Furthermore, :@0.084848:0.412461:0.481108:0.412479:0.481108:0.396723:0.084848:0.396705:0.005521:0.012315:0.012989:0.011507:0.012257:0.012315:0.005330:0.013381:0.005521:0.012315:0.006196:0.012315:0.009044:0.012257:0.003656:0.007274:0.003656:0.012411:0.011545:0.005330:0.013383:0.005600:0.012950:0.006331:0.012315:0.007274:0.005330:0.005900:0.005330:0.013381:0.009140:0.011507:0.005600:0.006331:0.011545:0.012315:0.006131:0.017857:0.012411:0.005519:0.012315:0.005328:0.401715
2:@0.334962:0.406860:0.341177:0.406860:0.341177:0.397675:0.334962:0.397675:0.006215
there was no difference in eight-year local :@0.084855:0.428658:0.481150:0.428658:0.481150:0.412903:0.084855:0.412903:0.006331:0.011545:0.012315:0.005521:0.012315:0.005696:0.015798:0.012950:0.007274:0.005696:0.011545:0.012411:0.005696:0.012989:0.003656:0.005905:0.005850:0.012315:0.005521:0.012315:0.011545:0.012257:0.012315:0.005696:0.003656:0.011545:0.005696:0.012315:0.003656:0.012758:0.011545:0.006331:0.006196:0.010122:0.012315:0.012950:0.005600:0.005696:0.003656:0.012411:0.012257:0.012950:0.003852:0.005330
recurrence rates (97%:@0.084855:0.444838:0.289646:0.444838:0.289646:0.429082:0.084855:0.429082:0.005521:0.012315:0.012257:0.011507:0.005600:0.005521:0.012315:0.011545:0.012257:0.012315:0.008207:0.005600:0.012950:0.006331:0.012315:0.007274:0.008205:0.006908:0.010468:0.010468:0.014913
 vs :@0.289453:0.444838:0.320730:0.444838:0.320730:0.429082:0.289453:0.429082:0.008205:0.010468:0.007274:0.005330
95%) or disease-:@0.323595:0.444838:0.475745:0.444838:0.475745:0.429082:0.323595:0.429082:0.010468:0.010468:0.014720:0.006908:0.008207:0.012411:0.005600:0.008207:0.012989:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.006388
free survival rates (89:@0.084855:0.461017:0.277410:0.461017:0.277410:0.445261:0.084855:0.445261:0.005850:0.005519:0.012315:0.012315:0.006158:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.006158:0.005600:0.012950:0.006331:0.012315:0.007274:0.006158:0.006908:0.010468:0.010660
 vs :@0.277217:0.461017:0.306446:0.461017:0.306446:0.445261:0.277217:0.445261:0.006158:0.010468:0.007274:0.005330
93%) in patients in :@0.307274:0.461017:0.481095:0.461031:0.481095:0.445275:0.307274:0.445261:0.010468:0.010468:0.014720:0.007100:0.009492:0.003656:0.011545:0.006158:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.006158:0.003656:0.011736:0.331107
3 :@0.349832:0.455412:0.359043:0.455412:0.359043:0.446226:0.349832:0.446226:0.006103:0.003107
whom preoperative MRI had been utilised, :@0.084857:0.477210:0.481108:0.477210:0.481108:0.461454:0.084857:0.461454:0.015798:0.011545:0.012411:0.017857:0.005426:0.012931:0.005519:0.012315:0.012411:0.012931:0.012315:0.005600:0.012950:0.006331:0.003656:0.010468:0.012315:0.005426:0.017491:0.011488:0.004156:0.005426:0.011545:0.012950:0.012989:0.005426:0.012931:0.012315:0.012315:0.011545:0.005426:0.011507:0.006331:0.003656:0.003656:0.003656:0.007274:0.012315:0.012989:0.005326:0.005330
compared to those who did not undergo :@0.084857:0.493390:0.481145:0.493390:0.481145:0.477634:0.084857:0.477634:0.012257:0.012411:0.017857:0.012931:0.012950:0.005521:0.012315:0.012989:0.007351:0.006331:0.012411:0.007351:0.006331:0.011545:0.012411:0.007274:0.012315:0.007351:0.015798:0.011545:0.012411:0.007351:0.012989:0.003656:0.012989:0.007351:0.011545:0.012411:0.006331:0.007351:0.011507:0.011545:0.012989:0.012315:0.005615:0.012758:0.012600:0.005330
preoperative MRI, based on a meta-analy-:@0.084857:0.509569:0.475745:0.509569:0.475745:0.493813:0.084857:0.493813:0.012931:0.005521:0.012315:0.012411:0.012931:0.012315:0.005600:0.012950:0.006331:0.003656:0.010468:0.012315:0.004849:0.017491:0.011488:0.004156:0.005138:0.004849:0.012931:0.012950:0.007274:0.012315:0.012989:0.004849:0.012411:0.011545:0.004849:0.012950:0.004849:0.017857:0.012315:0.006331:0.012950:0.006196:0.012950:0.011545:0.012950:0.003656:0.010122:0.006388
sis of in excess of 3 000 patients with newly :@0.084857:0.525748:0.481137:0.525748:0.481137:0.509992:0.084857:0.509992:0.007274:0.003656:0.007274:0.006042:0.012411:0.005850:0.006042:0.003656:0.011545:0.006042:0.012315:0.009044:0.012257:0.012315:0.007274:0.007274:0.006042:0.012411:0.005850:0.006042:0.010468:0.006042:0.010468:0.010468:0.010468:0.006042:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.006042:0.015798:0.003656:0.006331:0.011545:0.006042:0.011545:0.012315:0.015798:0.003656:0.010316:0.005330
diagnosed breast cancer.:@0.084857:0.541927:0.322181:0.541927:0.322181:0.526171:0.084857:0.526171:0.012989:0.003656:0.012950:0.012758:0.011545:0.012411:0.007274:0.012315:0.012989:0.005138:0.012931:0.005521:0.012315:0.012950:0.007274:0.006331:0.005138:0.012257:0.012950:0.011545:0.012257:0.012315:0.004185:0.005330
Indications for  an MRI of  the  breast in-:@0.103041:0.558107:0.475786:0.558107:0.475786:0.542351:0.103041:0.542351:0.004349:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.008428:0.006042:0.012604:0.005792:0.005330:0.003083:0.013143:0.011738:0.008428:0.017684:0.011680:0.004349:0.008428:0.012604:0.006042:0.005330:0.003088:0.006523:0.011738:0.012508:0.005330:0.003085:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.008428:0.003848:0.011738:0.006388
clude lobular cancer,  BRCA-positive pa-:@0.084857:0.574286:0.475768:0.574286:0.475768:0.558530:0.084857:0.558530:0.012450:0.003848:0.011699:0.013181:0.012508:0.009891:0.003848:0.012604:0.013123:0.011699:0.003848:0.013143:0.005792:0.009891:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.005330:0.004551:0.011045:0.011680:0.015644:0.014239:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.009891:0.013123:0.013143:0.006388
tients, or  patients harbouring other  high-:@0.084857:0.590465:0.475778:0.590465:0.475778:0.574709:0.084857:0.574709:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.009102:0.012604:0.005792:0.005330:0.003760:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009102:0.011738:0.013143:0.005792:0.013123:0.012604:0.011699:0.005792:0.003848:0.011738:0.012935:0.009102:0.012604:0.006523:0.011738:0.012508:0.005792:0.005330:0.003752:0.011738:0.003848:0.012950:0.011738:0.006388
risk mutations  and multifocal/multicentric :@0.084857:0.606644:0.481106:0.606644:0.481106:0.590888:0.084857:0.590888:0.005792:0.003848:0.007466:0.009660:0.008255:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.002915:0.013143:0.011738:0.013181:0.008255:0.018049:0.011699:0.003848:0.006523:0.003848:0.006042:0.012604:0.012450:0.013143:0.003848:0.008409:0.018049:0.011699:0.003848:0.006523:0.003848:0.012450:0.012508:0.011738:0.006523:0.005792:0.003848:0.012450:0.005330
breast cancer. Ongoing clinical trials are :@0.084857:0.622824:0.481095:0.622824:0.481095:0.607068:0.084857:0.607068:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.008140:0.012450:0.013143:0.011738:0.012450:0.012508:0.004376:0.005330:0.008140:0.016722:0.011738:0.012950:0.012604:0.003848:0.011738:0.012950:0.008140:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.008157:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.008151:0.013143:0.005715:0.012508:0.005330
evaluating the use of breast MRI to assess :@0.084857:0.639003:0.481114:0.639003:0.481114:0.623247:0.084857:0.623247:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.003848:0.011738:0.012950:0.006138:0.006523:0.011738:0.012508:0.006138:0.011699:0.007466:0.012508:0.006138:0.012604:0.006042:0.006129:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006138:0.017684:0.011680:0.004349:0.006138:0.006523:0.012604:0.006127:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.005330
response to neoadjuvant chemotherapy.:@0.084857:0.655182:0.469761:0.655182:0.469761:0.639426:0.084857:0.639426:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.006523:0.012604:0.005330:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
TREATMENT MODALITIES FOR  :@0.084848:0.688252:0.412179:0.688252:0.412179:0.668656:0.084848:0.668656:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878:0.006585:0.021167:0.019756:0.016463:0.017404:0.010348:0.006585:0.009878:0.006585:0.012230:0.012230:0.006585:0.011289:0.019756:0.013641:0.006538:0.006585
NON-METASTATIC BREAST CANCER:@0.084848:0.707380:0.473844:0.707380:0.473844:0.687783:0.084848:0.687783:0.017404:0.019756:0.017404:0.009878:0.021167:0.012230:0.009878:0.017404:0.012230:0.009878:0.017404:0.009878:0.006585:0.018344:0.006585:0.013641:0.013641:0.012230:0.017404:0.012230:0.009878:0.006585:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641
Treatment of non-metastatic breast can-:@0.084848:0.725853:0.475756:0.725853:0.475756:0.710097:0.084848:0.710097:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.008274:0.012604:0.006042:0.008274:0.011738:0.012604:0.011738:0.006388:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.008274:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.008274:0.012450:0.013143:0.011738:0.006388
cer is best managed in a multidisciplinary :@0.084848:0.742032:0.481076:0.742032:0.481076:0.726276:0.084848:0.726276:0.012450:0.012508:0.005792:0.006525:0.003848:0.007466:0.006542:0.013123:0.012508:0.007466:0.006523:0.006533:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.013181:0.006529:0.003848:0.011738:0.006533:0.013143:0.006542:0.018049:0.011699:0.003848:0.006523:0.003848:0.013181:0.003848:0.007466:0.012450:0.003848:0.013123:0.003848:0.003848:0.011738:0.013143:0.005792:0.010314:0.005330
team comprising  radiologists, breast sur-:@0.084848:0.758212:0.475767:0.758212:0.475767:0.742456:0.084848:0.742456:0.006523:0.012508:0.013143:0.018049:0.010102:0.012450:0.012604:0.018049:0.013123:0.005792:0.003848:0.007466:0.003848:0.011738:0.012950:0.005330:0.004762:0.005792:0.013143:0.013181:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.007466:0.005330:0.010102:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.010102:0.007466:0.011699:0.005792:0.006388
geons, plastic surgeons, medical and ra-:@0.084848:0.774391:0.475748:0.774391:0.475748:0.758635:0.084848:0.758635:0.012950:0.012508:0.012604:0.011738:0.007466:0.005330:0.007976:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.007999:0.007466:0.011699:0.005807:0.012950:0.012508:0.012604:0.011738:0.007466:0.005330:0.007976:0.018049:0.012508:0.013181:0.003848:0.012450:0.013143:0.003848:0.007986:0.013143:0.011738:0.013181:0.007986:0.005792:0.013143:0.006388
diation oncologists, as well as allied servic-:@0.084848:0.790570:0.475739:0.790570:0.475739:0.774814:0.084848:0.774814:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.004945:0.012604:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.007466:0.005330:0.004934:0.013143:0.007466:0.004945:0.015990:0.012508:0.003848:0.003848:0.004945:0.013143:0.007466:0.004945:0.013143:0.003848:0.003848:0.003848:0.012508:0.013181:0.004957:0.007466:0.012508:0.005792:0.010660:0.003848:0.012450:0.006388
es that include lymphoedema therapists, :@0.084848:0.806749:0.481113:0.806749:0.481113:0.790993:0.084848:0.790993:0.012508:0.007466:0.007812:0.006523:0.011738:0.013143:0.006523:0.007799:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007812:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012508:0.013181:0.012508:0.018049:0.013143:0.007812:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.007466:0.006523:0.007466:0.005330:0.005330
psychologists and dieticians.:@0.084848:0.822929:0.349855:0.822929:0.349855:0.807173:0.084848:0.807173:0.013123:0.007466:0.010314:0.012450:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.007466:0.005330:0.013143:0.011738:0.013181:0.005330:0.013181:0.003848:0.012508:0.006523:0.003848:0.012450:0.003848:0.013143:0.011738:0.007466:0.005330
The treatment consists of surgery, which :@0.103032:0.839108:0.481094:0.839108:0.481094:0.823352:0.103032:0.823352:0.008197:0.011738:0.012508:0.006240:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006240:0.012450:0.012604:0.011738:0.007466:0.003848:0.007466:0.006523:0.007466:0.006254:0.012604:0.006042:0.006244:0.007466:0.011699:0.005809:0.012950:0.012508:0.005792:0.010314:0.005330:0.006244:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330
could be a lumpectomy, mastectomy or :@0.084848:0.855287:0.481090:0.855287:0.481090:0.839531:0.084848:0.839531:0.012450:0.012604:0.011699:0.003848:0.013181:0.007568:0.013123:0.012508:0.007568:0.013143:0.007570:0.003848:0.011699:0.018049:0.013123:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.007562:0.018049:0.013143:0.007466:0.006523:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.007564:0.012604:0.005792:0.005330
bilateral mastectomy, chemotherapy with :@0.084848:0.871466:0.481088:0.871466:0.481088:0.855711:0.084848:0.855711:0.013123:0.003848:0.003848:0.013143:0.006523:0.012508:0.005792:0.013143:0.003848:0.004541:0.018049:0.013143:0.007466:0.006523:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.004526:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004528:0.015990:0.003848:0.006523:0.011738:0.005330
or without HER2-blockade in appropriate :@0.084848:0.887646:0.481099:0.887646:0.481099:0.871890:0.084848:0.871890:0.012604:0.005792:0.008157:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.008161:0.013143:0.010314:0.011680:0.010660:0.006388:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.008178:0.003848:0.011738:0.008166:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330
patients  (HER2-positive), radiation  treat-:@0.084848:0.903825:0.475752:0.903825:0.475752:0.888069:0.084848:0.888069:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.007707:0.007100:0.013143:0.010314:0.011680:0.010660:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.007100:0.005330:0.013046:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.007705:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment and hormonal blockade in patients :@0.084848:0.920004:0.481074:0.920004:0.481074:0.904248:0.084848:0.904248:0.018049:0.012508:0.011738:0.006523:0.006600:0.013143:0.011738:0.013181:0.006600:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.006600:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.006600:0.003848:0.011738:0.006600:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
whose tumours are endocrine-responsive.:@0.084848:0.936184:0.472023:0.936184:0.472023:0.920428:0.084848:0.920428:0.015990:0.011738:0.012604:0.007466:0.012508:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.013143:0.005694:0.012508:0.005330:0.012508:0.011738:0.013181:0.012604:0.012450:0.005792:0.003848:0.011738:0.012508:0.006388:0.005696:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.010660:0.012508:0.005330
Treatment  for  breast cancer  is personal-:@0.524249:0.096105:0.915164:0.096105:0.915164:0.080349:0.524249:0.080349:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.004197:0.006042:0.012604:0.005792:0.005330:0.004197:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.009544:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.004199:0.003848:0.007466:0.009544:0.013123:0.012508:0.005792:0.007466:0.012604:0.011738:0.013143:0.003848:0.006388
ised, based on patient factors including :@0.524249:0.112456:0.920507:0.112456:0.920507:0.096700:0.524249:0.096700:0.003848:0.007466:0.012508:0.013181:0.005330:0.009621:0.013123:0.013143:0.007466:0.012508:0.013181:0.009621:0.012604:0.011738:0.009621:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.009621:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.009621:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330
comorbidities,  tumour  factors  (biology), :@0.524249:0.128808:0.920490:0.128808:0.920490:0.113052:0.524249:0.113052:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.005330:0.008182:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.008170:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.008184:0.007100:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.007100:0.005330:0.005330
staging, and so on. A “one-size-fits-all” ap-:@0.524249:0.145159:0.915158:0.145159:0.915158:0.129403:0.524249:0.129403:0.007466:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.005330:0.005178:0.013143:0.011738:0.013181:0.005182:0.007466:0.012604:0.005180:0.012604:0.011738:0.005330:0.005172:0.014239:0.005178:0.009660:0.012604:0.011738:0.012508:0.006388:0.007466:0.003848:0.008178:0.012508:0.006388:0.004686:0.004686:0.006523:0.007466:0.006388:0.013143:0.003848:0.003848:0.009313:0.005186:0.013143:0.013123:0.006388
proach is not appropriate, and each case :@0.524249:0.161510:0.920490:0.161510:0.920490:0.145754:0.524249:0.145754:0.013123:0.005715:0.012604:0.013143:0.012450:0.011738:0.004753:0.003848:0.007466:0.004753:0.011738:0.012604:0.006523:0.004753:0.013143:0.013123:0.013123:0.005717:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330:0.004753:0.013143:0.011738:0.013181:0.004753:0.012508:0.013143:0.012450:0.011738:0.004753:0.012450:0.013143:0.007466:0.012508:0.005330
needs to be evaluated looking at the fac-:@0.524249:0.177861:0.915158:0.177861:0.915158:0.162105:0.524249:0.162105:0.011738:0.012508:0.012508:0.013181:0.007466:0.005118:0.006523:0.012604:0.005118:0.013123:0.012508:0.005118:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.005118:0.003848:0.012604:0.012604:0.009660:0.003848:0.011738:0.012950:0.005118:0.013143:0.006523:0.005118:0.006523:0.011738:0.012508:0.005118:0.006042:0.013143:0.012450:0.006388
tors mentioned above.:@0.524249:0.194213:0.737358:0.194213:0.737358:0.178457:0.524249:0.178457:0.006523:0.012604:0.005792:0.007466:0.005330:0.018049:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.012508:0.013181:0.005330:0.013143:0.013123:0.012604:0.010660:0.012508:0.005330
SURGERY:@0.524242:0.227344:0.616178:0.227344:0.616178:0.209528:0.524242:0.209528:0.011118:0.013683:0.012401:0.017960:0.011118:0.012401:0.013256
The choice of surgery is influenced by the :@0.524242:0.244847:0.920501:0.244847:0.920501:0.229091:0.524242:0.229091:0.008197:0.011738:0.012508:0.006161:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.006173:0.012604:0.006042:0.006165:0.007466:0.011699:0.005807:0.012950:0.012508:0.005792:0.010314:0.006165:0.003848:0.007466:0.006177:0.003848:0.011738:0.004666:0.004666:0.011699:0.012508:0.011738:0.012450:0.012508:0.013181:0.006167:0.013123:0.010314:0.006175:0.006523:0.011738:0.012508:0.005330
size of the tumour, the location within the :@0.524242:0.261198:0.920508:0.261198:0.920508:0.245442:0.524242:0.245442:0.007466:0.003848:0.008178:0.012508:0.006850:0.012604:0.006042:0.006835:0.006523:0.011738:0.012508:0.006833:0.006523:0.011699:0.018049:0.012604:0.011699:0.003762:0.005330:0.006837:0.006523:0.011738:0.012508:0.006833:0.003848:0.012604:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.006835:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.006850:0.006523:0.011738:0.012508:0.005330
breast, the presence or absence of delete-:@0.524242:0.277550:0.915170:0.277550:0.915170:0.261794:0.524242:0.261794:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330:0.003483:0.006523:0.011738:0.012508:0.003483:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.003483:0.012604:0.005792:0.003483:0.013143:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.003483:0.012604:0.006042:0.003483:0.013181:0.012508:0.003848:0.012508:0.006523:0.012508:0.006388
rious mutations, and patient preferences.:@0.524242:0.293901:0.906944:0.293901:0.906944:0.278145:0.524242:0.278145:0.005792:0.003848:0.012604:0.011699:0.007466:0.005330:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.013123:0.005694:0.012508:0.006042:0.012508:0.005707:0.012508:0.011738:0.012450:0.012508:0.007466:0.005330
The timing of surgery is determined by :@0.542426:0.310252:0.920531:0.310252:0.920531:0.294496:0.542426:0.294496:0.008390:0.011930:0.012700:0.007851:0.006716:0.004041:0.018242:0.004041:0.011930:0.013143:0.007851:0.012796:0.006235:0.007851:0.007658:0.011892:0.006000:0.013143:0.012700:0.005984:0.010506:0.007851:0.004041:0.007658:0.007851:0.013373:0.012700:0.006716:0.012700:0.006515:0.018242:0.004041:0.011930:0.012700:0.013373:0.007851:0.013316:0.010318:0.005330
the initial stage of the cancer,  tumour :@0.524242:0.326603:0.920474:0.326603:0.920474:0.310847:0.524242:0.310847:0.006716:0.011930:0.012700:0.011238:0.004041:0.011930:0.004041:0.006716:0.004041:0.013335:0.004041:0.011238:0.007658:0.006716:0.013335:0.013143:0.012700:0.011238:0.012796:0.006235:0.011238:0.006716:0.011930:0.012700:0.011238:0.012642:0.013335:0.011930:0.012642:0.012700:0.003960:0.005523:0.005330:0.005907:0.006716:0.011892:0.018242:0.012796:0.011892:0.005788:0.005330
size, and the use of neoadjuvant chemo-:@0.524242:0.342955:0.915170:0.342955:0.915170:0.327199:0.524242:0.327199:0.007658:0.004041:0.008370:0.012700:0.005523:0.005619:0.013335:0.011930:0.013373:0.005619:0.006716:0.011930:0.012700:0.005619:0.011892:0.007658:0.012700:0.005619:0.012796:0.006235:0.005619:0.011930:0.012700:0.012796:0.013335:0.013373:0.004099:0.011892:0.010853:0.013335:0.011930:0.006716:0.005619:0.012642:0.011930:0.012700:0.018242:0.012796:0.006388
therapy.:@0.524242:0.359306:0.604059:0.359306:0.604059:0.343550:0.524242:0.343550:0.006716:0.011930:0.012700:0.005984:0.013335:0.013316:0.010506:0.005330
The trend towards bilateral mastec-:@0.542426:0.375657:0.915145:0.375657:0.915145:0.359901:0.542426:0.359901:0.008197:0.011738:0.012508:0.015933:0.006523:0.005709:0.012508:0.011738:0.013181:0.015933:0.006523:0.012604:0.015990:0.013143:0.005677:0.013181:0.007466:0.015933:0.013123:0.003848:0.003848:0.013143:0.006523:0.012508:0.005792:0.013143:0.003848:0.015933:0.018049:0.013143:0.007466:0.006523:0.012508:0.012450:0.006388
tomies  has been  increasing  across the :@0.524242:0.392008:0.920501:0.392008:0.920501:0.376252:0.524242:0.376252:0.006523:0.012604:0.018049:0.003848:0.012508:0.007466:0.005330:0.007204:0.011738:0.013143:0.007466:0.012546:0.013123:0.012508:0.012508:0.011738:0.005330:0.007202:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.003848:0.011738:0.012950:0.005330:0.007204:0.013143:0.012450:0.005715:0.012604:0.007466:0.007466:0.012546:0.006523:0.011738:0.012508:0.005330
globe,  fuelled by media awareness and :@0.524242:0.408360:0.920485:0.408360:0.920485:0.392604:0.524242:0.392604:0.012950:0.003848:0.012604:0.013123:0.012508:0.005330:0.005330:0.003664:0.006042:0.011699:0.012508:0.003848:0.003848:0.012508:0.013181:0.009005:0.013123:0.010314:0.009005:0.018049:0.012508:0.013181:0.003848:0.013143:0.009005:0.013143:0.015990:0.013143:0.005711:0.012508:0.011738:0.012508:0.007466:0.007466:0.009005:0.013143:0.011738:0.013181:0.005330
celebrities who have undergone this pro-:@0.524242:0.424711:0.915140:0.424711:0.915140:0.408955:0.524242:0.408955:0.012450:0.012508:0.003848:0.012508:0.013123:0.005792:0.003848:0.006523:0.003848:0.012508:0.007466:0.007197:0.015990:0.011738:0.012604:0.007197:0.011738:0.013143:0.010660:0.012508:0.007197:0.011699:0.011738:0.013181:0.012508:0.005792:0.012950:0.012604:0.011738:0.012508:0.007185:0.006523:0.011738:0.003848:0.007466:0.007197:0.013123:0.005715:0.012604:0.006388
cedure.  Contralateral prophylactic mas-:@0.524242:0.441062:0.915157:0.441062:0.915157:0.425306:0.524242:0.425306:0.012450:0.012508:0.013181:0.011699:0.005709:0.012508:0.005330:0.005330:0.004449:0.015644:0.012604:0.011738:0.006523:0.005792:0.013131:0.003848:0.013143:0.006523:0.012508:0.005792:0.013143:0.003848:0.009794:0.013123:0.005715:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.012450:0.006523:0.003848:0.012450:0.009794:0.018049:0.013143:0.007466:0.006388
tectomy  does  not  confer  a survival ben-:@0.524242:0.457413:0.915147:0.457413:0.915147:0.441657:0.524242:0.441657:0.006523:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.003025:0.013181:0.012604:0.012508:0.007466:0.005330:0.003031:0.011738:0.012604:0.006523:0.005330:0.003025:0.012450:0.012604:0.011738:0.006042:0.012508:0.005792:0.005330:0.003019:0.013143:0.008370:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.008370:0.013123:0.012508:0.011738:0.006388
efit,  except  in  patients  with  a  hereditary :@0.524242:0.473765:0.920481:0.473765:0.920481:0.458009:0.524242:0.458009:0.012508:0.004686:0.004686:0.006523:0.005330:0.005330:0.003639:0.012508:0.009236:0.012450:0.012508:0.013123:0.006523:0.005330:0.003648:0.003848:0.011738:0.005330:0.003650:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.003650:0.015990:0.003848:0.006523:0.011738:0.005330:0.003648:0.013143:0.005330:0.003650:0.011738:0.012508:0.005707:0.012508:0.013181:0.003848:0.006523:0.013143:0.005792:0.010314:0.005330
breast cancer.:@0.524242:0.490116:0.660041:0.490116:0.660041:0.474360:0.524242:0.474360:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004374:0.005330
4:@0.660038:0.484581:0.666253:0.484581:0.666253:0.475395:0.660038:0.475395:0.006215
CHEMOTHERAPY:@0.524242:0.523237:0.691865:0.523237:0.691865:0.505421:0.524242:0.505421:0.016677:0.014539:0.011118:0.019242:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
Not all patients with breast cancer require :@0.524242:0.540740:0.920485:0.540740:0.920485:0.524984:0.524242:0.524984:0.014239:0.012604:0.006523:0.005332:0.013143:0.003848:0.003848:0.005349:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005349:0.015990:0.003848:0.006523:0.011738:0.005349:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005349:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005334:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.005330
chemotherapy.  This is based largely on :@0.524242:0.557091:0.920499:0.557091:0.920499:0.541335:0.524242:0.541335:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.005923:0.008197:0.011738:0.003848:0.007466:0.011276:0.003848:0.007466:0.011276:0.013123:0.013143:0.007466:0.012508:0.013181:0.011276:0.003848:0.013143:0.005813:0.012950:0.012508:0.003848:0.010314:0.011276:0.012604:0.011738:0.005330
disease biology and chemotherapy sensi-:@0.524242:0.573442:0.915157:0.573442:0.915157:0.557687:0.524242:0.557687:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005888:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.005888:0.013143:0.011738:0.013181:0.005888:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011724:0.012508:0.005792:0.013143:0.013123:0.010314:0.005888:0.007466:0.012508:0.011738:0.007466:0.003848:0.006388
tivity of a particular type of breast cancer, :@0.524242:0.589794:0.920466:0.589794:0.920466:0.574038:0.524242:0.574038:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005303:0.012604:0.006042:0.005292:0.013143:0.005292:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.005292:0.006523:0.010314:0.013123:0.012508:0.005292:0.012604:0.006042:0.005292:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005292:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.005330
the intensity of oestrogen receptor and :@0.524242:0.606145:0.920491:0.606145:0.920491:0.590389:0.524242:0.590389:0.006523:0.011738:0.012508:0.010622:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.003848:0.006523:0.010314:0.010622:0.012604:0.006042:0.010622:0.012604:0.012508:0.007466:0.006523:0.005707:0.012604:0.012950:0.012508:0.011738:0.010622:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.010622:0.013143:0.011738:0.013181:0.005330
progesterone  receptor  expression, and :@0.524242:0.622496:0.920481:0.622496:0.920481:0.606740:0.524242:0.606740:0.013123:0.005715:0.012604:0.012950:0.012508:0.007466:0.006523:0.012508:0.005703:0.012604:0.011738:0.012508:0.005330:0.009381:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.009377:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.014720:0.013143:0.011738:0.013181:0.005330
HER2 neu status.:@0.524242:0.638847:0.674794:0.638847:0.674794:0.623092:0.524242:0.623092:0.013143:0.010314:0.011680:0.010660:0.005330:0.011738:0.012508:0.011699:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330
Indications for neoadjuvant :@0.524242:0.671918:0.814161:0.671918:0.814161:0.653897:0.524242:0.653897:0.005987:0.012828:0.014111:0.005131:0.013683:0.014111:0.006414:0.005131:0.013683:0.012828:0.009407:0.005987:0.005987:0.013683:0.006842:0.005987:0.012828:0.013683:0.013683:0.014111:0.014111:0.005559:0.012828:0.011973:0.014111:0.012828:0.006414:0.005987
chemotherapy:@0.524242:0.689748:0.678609:0.689748:0.678609:0.671727:0.524242:0.671727:0.013683:0.012828:0.013683:0.020098:0.013683:0.006414:0.012828:0.013683:0.006842:0.014111:0.014111:0.012401
Locally advanced breast cancer – Stage :@0.524242:0.707248:0.920483:0.707248:0.920483:0.691492:0.524242:0.691492:0.008890:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.006985:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.006985:0.013123:0.005717:0.012508:0.013143:0.007466:0.006523:0.006985:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.006985:0.009621:0.006985:0.009583:0.006523:0.013143:0.012950:0.012508:0.005330
IIB-IIIC tumours (see Table 1) must be con-:@0.524242:0.723599:0.915159:0.723599:0.915159:0.707843:0.524242:0.707843:0.004349:0.004349:0.011045:0.006388:0.004349:0.004349:0.004349:0.015644:0.006081:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.006069:0.007100:0.007466:0.012508:0.012508:0.006081:0.007197:0.013143:0.013123:0.003848:0.012508:0.006081:0.010660:0.007100:0.006081:0.018049:0.011699:0.007466:0.006523:0.006081:0.013123:0.012508:0.006081:0.012450:0.012604:0.011738:0.006388
sidered  for  neoadjuvant  chemotherapy, :@0.524242:0.739951:0.920497:0.739951:0.920497:0.724195:0.524242:0.724195:0.007466:0.003848:0.013181:0.012508:0.005719:0.012508:0.013181:0.005330:0.005145:0.006042:0.012604:0.005792:0.005330:0.005138:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.005142:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
as they are often too large for upfront re-:@0.524242:0.756302:0.915197:0.756302:0.915197:0.740546:0.524242:0.740546:0.013143:0.007466:0.006504:0.006523:0.011738:0.012508:0.010314:0.006504:0.013143:0.005715:0.012508:0.006504:0.012604:0.006042:0.006523:0.012508:0.011738:0.006504:0.006523:0.012604:0.012604:0.006490:0.003848:0.013143:0.005811:0.012950:0.012508:0.006504:0.006042:0.012604:0.005792:0.006504:0.011699:0.013123:0.006042:0.005713:0.012604:0.011738:0.006523:0.006490:0.005713:0.012508:0.006388
section.  In  addition,  smaller tumours  with :@0.524242:0.772653:0.920479:0.772653:0.920479:0.756897:0.524242:0.756897:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.003140:0.004349:0.011738:0.005330:0.003144:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.003140:0.007466:0.018049:0.013143:0.003848:0.003848:0.012508:0.005792:0.008486:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.003138:0.015990:0.003848:0.006523:0.011738:0.005330
an unfavourable tumour-to-breast ratio :@0.524242:0.789004:0.920479:0.789004:0.920479:0.773248:0.524242:0.773248:0.013143:0.011738:0.013797:0.011699:0.011738:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.013797:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006388:0.006523:0.012604:0.006367:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.013797:0.005792:0.013143:0.006523:0.003848:0.012604:0.005330
are  considered for  neoadjuvant thera-:@0.524242:0.805356:0.915151:0.805356:0.915151:0.789600:0.524242:0.789600:0.013143:0.005715:0.012508:0.005330:0.007918:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005717:0.012508:0.013181:0.013258:0.006042:0.012604:0.005792:0.005330:0.007911:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.013258:0.006523:0.011738:0.012508:0.005792:0.013110:0.006388
py, as this may improve the likelihood of :@0.524242:0.821707:0.920485:0.821707:0.920485:0.805951:0.524242:0.805951:0.013123:0.010314:0.005330:0.008120:0.013143:0.007466:0.008120:0.006523:0.011738:0.003848:0.007466:0.008120:0.018049:0.013143:0.010314:0.008120:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.008120:0.006523:0.011738:0.012508:0.008120:0.003848:0.003848:0.009660:0.012508:0.003848:0.003848:0.011738:0.012604:0.012604:0.013181:0.008120:0.012604:0.006042:0.005330
breast conservation.:@0.524242:0.838058:0.714453:0.838058:0.714453:0.822302:0.524242:0.822302:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.012604:0.011738:0.007466:0.012508:0.005792:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
Smaller tumours with an unfavourable :@0.542426:0.854409:0.920508:0.854409:0.920508:0.838653:0.542426:0.838653:0.009583:0.018049:0.013143:0.003848:0.003848:0.012508:0.005792:0.010795:0.006523:0.011699:0.018049:0.012604:0.011688:0.005792:0.007466:0.010795:0.015990:0.003848:0.006523:0.011738:0.010795:0.013143:0.011738:0.010795:0.011699:0.011738:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330
biology  (triple-negative  breast cancer, :@0.524242:0.870761:0.920489:0.870761:0.920489:0.855005:0.524242:0.855005:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.005330:0.010920:0.007100:0.006523:0.005792:0.003848:0.013123:0.003848:0.012508:0.006388:0.011738:0.012508:0.012950:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.010916:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.016260:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.005330
HER2-overexpressors) are often treated :@0.524242:0.887112:0.920476:0.887112:0.920476:0.871356:0.524242:0.871356:0.013143:0.010314:0.011680:0.010660:0.006388:0.012604:0.010660:0.012508:0.005719:0.012508:0.009236:0.013123:0.005711:0.012508:0.007466:0.007466:0.012604:0.005792:0.007466:0.007100:0.015125:0.013143:0.005715:0.012508:0.015125:0.012604:0.006042:0.006523:0.012508:0.011738:0.015125:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330
with neoadjuvant chemotherapy,  as :@0.524242:0.903463:0.920497:0.903463:0.920497:0.887707:0.524242:0.887707:0.015990:0.003848:0.006523:0.011738:0.021859:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.021859:0.012450:0.011738:0.012508:0.018049:0.012604:0.006512:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.016518:0.013143:0.007466:0.005330
these  tumours  are  chemotherapy-sensi-:@0.524242:0.919814:0.915142:0.919814:0.915142:0.904058:0.524242:0.904058:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.007564:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007456:0.005330:0.007570:0.013143:0.005715:0.012508:0.005330:0.007568:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011722:0.012508:0.005792:0.013143:0.013123:0.010314:0.006388:0.007466:0.012508:0.011738:0.007466:0.003848:0.006388
tive, and the patients will be candidates :@0.524242:0.936166:0.920476:0.936166:0.920476:0.920410:0.524242:0.920410:0.006523:0.003848:0.010660:0.012508:0.005330:0.007995:0.013143:0.011738:0.013181:0.008005:0.006523:0.011738:0.012508:0.007989:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007995:0.015990:0.003848:0.003848:0.003848:0.008005:0.013123:0.012508:0.007995:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.005330